BCTX

BriaCell

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 4

Sell signal 3

stock price surged significantly

consensus rating "Strong Buy"

ample liquidity

Net Income Plunges

EPS Beats Expectation

Price Hits New Low

Price Hits 52-week low

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About BCTX

Briacell Therapeutics Corp.

A clinical-stage biotechnology company that specializing in targeted immunotherapies for cancer

Industry

Biological Technology

Established Date

07/26/2006

Listing Date

02/24/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

07-31

Website

briacell.com

Security Type

Common stock

Office address

235 15th Street, Suite 300, West Vancouver, BC, V7T 2X1

Business

Introduction

BriaCell Therapeutics Corp. was founded in British Columbia on July 26, 2006. The company is a clinical-stage biotechnology company that is developing new immunotherapies to transform cancer treatment. Immunotherapies are at the forefront of the fight against cancer because they use the body's own immune system to identify and destroy cancer cells. The company is currently advancing a pivotal Phase 1 Phase 3 study of its Bria-IMT targeted immunotherapy in combination with immune checkpoint inhibitors for advanced metastatic breast cancer.

Company Financials

EPS

BCTX has released its 2023 Q3 earnings. EPS was reported at -0.32, versus the expected -0.47, beating expectations. The chart below visualizes how BCTX has performed over recent quarters, highlighting trends in earnings surprises.